HIGHLIGHTS
- who: Canadian cohort expanded-access and collaborators from the (UNIVERSITY) have published the research: Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma, in the Journal: (JOURNAL) of 24/01/2018
- what: The authors report updated safety and os data for the Canadian cohort, with a median follow-up of 12.9 months.
SUMMARY
Before the era of immune checkpoint inhibition, median overall survival (os) for patients with advanced melanoma ranged from 6 months to 12 months1; today, it is 4 years or longer2. From randomized clinical trials . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.